Related Experiment Video
Updated: Jun 20, 2026
Transcutaneous Neuromuscular Electrical Stimulation for Treating Varicocele-Induced Scrotal Pain
Published on: August 30, 2024
Therapeutic options following orchiectomy for stage I seminoma
Nathan Lawrentschuk1, Neil E Fleshner
1Division of Urologic Oncology, University of Toronto, University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada.
Abstract:
Stage I seminoma represents the paradigm of a curable malignancy, with survival of 100% an expected outcome no matter what treatment option is chosen. However, consensus has not been reached among urologists and oncologists regarding the optimal postoperative management in men with clinical stage I testicular seminoma. Currently, men are offered active surveillance, adjuvant radiation therapy, or single-agent chemotherapy. Active surveillance is associated with an 80% chance of no relapse, with all such events salvageable. Radiotherapy has an almost universal cure rate but has the potential for long-term toxicities and an overtreatment rate of about 80%. Chemotherapy efficacy and toxicity data are still immature. Recent guidelines recognize that the options of surveillance, chemotherapy, and radiotherapy are appropriate in the treatment of patients with clinical stage I seminoma. We believe active surveillance to be the best option, then radiotherapy (considering the efficacy and safety data), with single-agent chemotherapy emerging as a possible alternative.
Insights
For stage I seminoma, active surveillance offers an 80% chance of no relapse and is the preferred treatment. Radiotherapy and chemotherapy are alternatives for testicular cancer management.
Area of Science:
- Oncology
- Urology
Background:
- Stage I seminoma is a highly curable malignancy with a 100% survival rate.
- Optimal postoperative management for clinical stage I testicular seminoma remains debated among specialists.
Observation:
- Current management options include active surveillance, adjuvant radiation therapy, or single-agent chemotherapy.
- Active surveillance has an 80% non-relapse rate, with relapses being salvageable.
- Radiation therapy offers high cure rates but carries risks of long-term toxicity and overtreatment (approx. 80%).
- Chemotherapy data regarding efficacy and toxicity are still limited.
Findings:
- Recent guidelines support surveillance, chemotherapy, and radiotherapy as appropriate treatments for stage I seminoma.
- The authors advocate for active surveillance as the primary option.
- Radiotherapy is considered a viable second option due to efficacy and safety data.
- Single-agent chemotherapy is presented as a potential alternative.
Implications:
- Active surveillance is recommended as the optimal initial management strategy for stage I testicular seminoma.
- Radiation therapy should be considered cautiously due to potential long-term toxicities.
- Further research is needed to fully establish the role of single-agent chemotherapy.
